CSL (CSLLY) Beginning Cash Position: $2,157 Mil (As of Dec. 2025)


CSLLY CSL Ltd CSLLY
73 GF Score
Price $20.06
GF Value $51.03
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is CSL Beginning Cash Position?

CSL CSLLY -0.30% 73 Beginning Cash Position is $2,157 Mil as of Dec. 2025. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $51.03 (Significantly Undervalued). The stock has 7 warning signs investors should review.

CSL's Beginning Cash Position for the quarter that ended in Dec. 2025 was $2,157 Mil.

CSL's quarterly Beginning Cash Position declined from Jun. 2024 ($1,011 Mil) to Jun. 2025 ($0 Mil) but then increased from Jun. 2025 ($0 Mil) to Dec. 2025 ($2,157 Mil).

CSL's annual Beginning Cash Position declined from Jun. 2023 ($10,334 Mil) to Jun. 2024 ($1,509 Mil) but then increased from Jun. 2024 ($1,509 Mil) to Jun. 2025 ($1,643 Mil).

CSL Beginning Cash Position Related Terms

CSL Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for CSL's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL Beginning Cash Position Chart

CSL Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,151.30 1,730.10 10,334.00 1,509.00 1,643.00

CSL Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,457.30 1,509.00 1,011.00 0.00 2,157.00
CSLLY
73GF Score
CSL Ltd CSLLY
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSL Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $2,157 Mil mean?
CSL (CSLLY) has a Beginning Cash Position of $2,157 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on CSL and its competitors.
Is CSL's Beginning Cash Position too high?
CSL's current Beginning Cash Position is $2,157 Mil. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Beginning Cash Position compare to VRTX and REGN?
CSL's Beginning Cash Position of $2,157 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on CSL and its competitors. CSL's current Beginning Cash Position is $2,157 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $51.03, compared to a current price of $20.06 — trading 60.7% below its estimated fair value. The current Beginning Cash Position is $2,157 Mil. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For CSL (CSLLY), the current Beginning Cash Position is $2,157 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (CSLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of $20.06 is trading 60.7% below its estimated GF Value™ of $51.03. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for CSLLY:

  • Beginning Cash Position: $2,157 Mil
  • GF Value™: $51.03 vs. price of $20.06 (60.7% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score

Get the complete analysis for CSLLY

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.06
Price
$51.03
GF Value